

Ref: 77/SE/LC/2025-26

Date: February 09, 2026

Scrip Code BSE: 544122
NSE: ENTERO
ISIN: INE010601016

To,
Head, Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001

Head, Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Dear Sir/Madam,

Subject: Submission of information pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 - Media Release/ Press Release

Please find enclosed a copy of the Media Release / Press Release, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, titled "Acquisition Update: Entero Healthcare acquires 51.5% stake in Anand Chemiceutics - A leading diagnostic and MedTech solutions provider" as **Annexure -1**.

The above-mentioned Media Release / Press Release will also be available on website of the Company at www.enterohealthcare.com.

This is for your information and records.

Yours Faithfully
For Entero Healthcare Solutions Limited

Sanu Kapoor
**Vice President- General Counsel, Company Secretary
& Compliance Officer**

Encl: As above

PRESS RELEASE

Acquisition Update: Enterو Healthcare acquires 51.5% stake in Anand Chemiceutics – A leading diagnostic and MedTech solutions provider

- Scales presence in large and high-growth MedTech market
- Creates opportunities for leveraging collective distribution strength, partnership, geographical reach and expertise
- Accelerating on the vision to create an integrated and comprehensive healthcare supply chain solutions provider

Monday, 09th February 2026, Mumbai: Enterو Healthcare Solutions Limited, India's leading and fastest-growing distributor of healthcare products, announces successful closing of the acquisition of Anand Chemiceutics Private Limited.

Anand Chemiceutics is an industry-leading distributor of diagnostic products and preferred channel partner for global diagnostic and MedTech product companies. With over two decades of established trust, legacy, and technical expertise in diagnostic and MedTech products, the acquisition solidifies Enterو's position in the fast-growing segment. The company has a strong pan-India presence and customer service network of more than 1,500 laboratories, hospitals and government institutions. Its specialized capabilities include distribution, marketing, application and service support for diagnostic equipment and reagents including advanced genomics. The company is also a leading turnkey solutions provider for hospitals and laboratories.

Commenting on this development, Mr. Prabhat Agrawal, MD and CEO, Enterو Healthcare said, "I am pleased to welcome Anand Chemiceutics to Enterو group. Its extensive track record, partnerships with global diagnostics players and expertise in MedTech combined with our distribution reach, capabilities and resources strategically positions us to build scale in this attractive segment."

Commenting on this development, Mr. Jayesh Sancheti, MD, Anand Chemiceutics said, "This is more than a partnership — it's the strategic integration of Anand Chemiceutics legacy trust in diagnostics and MedTech distribution with Enterو's scale and technology, creating a powerhouse that creates meaningful difference in patients' lifecycle."

Enterو Healthcare had announced the acquisition on November 12, 2025. With this, MedTech segment is expected to contribute more than ~INR 1,000 Cr in annualised revenue in the next financial year.

About Anand Chemiceutics Private Limited

Established in 2003, Anand Chemiceutics Private Limited is a trusted pan-India healthcare distribution partner, delivering advanced diagnostics and medical devices, allied products, and end-to-end turnkey solutions. With deep expertise across PPP projects, chain laboratories, diagnostic networks, and hospitals, the company enables healthcare institutions to scale efficiently and deliver superior patient outcomes. Headquartered in Pune, with a strong regional presence in Mumbai, Gurugram, and Bengaluru, Anand Chemiceutics combines nationwide reach with on-ground execution excellence.

About Enterro Healthcare Solutions Limited

Enterro Healthcare Solutions Limited (Enterro) is one of India's leading and fastest-growing healthcare products distribution platforms. Established in 2018, Enterro has rapidly scaled to become a key player in the pharmaceutical supply chain. Driven by a proprietary technology platform, Enterro enables seamless integration of data intelligence, demand generation, and fulfilment solutions. Through its flagship B2B app, Enterro Direct, the company delivers real-time inventory visibility, efficient order management, and tailored customer engagement tools. Enterro's commitment to operational excellence is supported by its experienced leadership team, a healthcare-focused investor base, and a relentless pursuit of innovation. By combining a customer-centric approach with advanced logistics infrastructure, Enterro is reshaping India's fragmented healthcare distribution landscape, ensuring accessibility, affordability, and efficiency in healthcare delivery.

Safe Harbor

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information please contact:



Enterro Healthcare Solutions Limited

CIN: L74999HR2018PLC072204

Ms. Akanksha Gupta

Email: irentero@ehspl.com

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya / Parin Narichania

Email: jigar.kavaiya@sgapl.net / parin.n@sgapl.net

Contact no.: +91 9920602034 / +91 9930025733